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Chau-To Kwok1,2,3, Amy D. Marshall1,3, John E. J. Rasko1,3,4 and Justin J. L. Wong1,2,3*Erratum
The original article [1] contained an error whereby the
formatting of Table 1 was not presented correctly; this
error has now been corrected.
Furthermore, the error was mistakenly carried forward
by the production team handling this article, and thus
was not the fault of the authors.
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Table 1 Clinical and molecular characteristics of TCGA AML patients according to the mutation and/or copy number variation status
of genes encoding m6A regulatory enzymes
Mutation and/or CNV CNV onlya Mutation
Yes (n = 23) No (n = 168) P Yes (n = 18) No (n = 168) P Yes (n = 5) No (n = 186) P
Age 0.083 0.193 0.205
Median (range) 65 (18–81) 57 (21–88) 62.5 (18–81) 57 (21–88) 65 (45–76) 57.5 (18–88)
Sex, no. (%) 0.123 0.321 0.376
Male 16 (8.4) 87 (45.5) 12 (6.5) 87 (46.8) 4 (2.1) 99 (51.8)
Female 7 (3.7) 81 (42.4) 6 (3.2) 81 (43.5) 1 (0.5) 87 (45.5)
BM blast 0.072 0.038 0.915
Median % (range) 60 (30–97) 73 (30–100) 54 (30–97) 73 (30–100) 75 (33–90) 72 (30–100)
WBC, ×103/mm3 0.084 0.047 0.889
Median (range) 5.4 (0.7–202.7) 17.5 (0.4–298.4) 5.2 (2.3–101.3) 17.45 (0.4–298.4) 14.5 (2.3–101.3) 15.6 (0.4–298.4)
Cytogenetic risk, no. (%) <0.0001 <0.0001 0.483
Favorable 0 (0) 37 (19.4) 0 (0) 37 (19.9) 0 (0) 37 (19.4)
Intermediate 4 (2.1) 105 (55) 1 (0.5) 105 (56.5) 3 (1.6) 106 (55.5)
Unfavorable 19 (9.9) 21 (11) 17 (9.1) 21 (11.3) 2 (1) 38 (19.9)
Missing data 0 (0) 5 (2.6) 0 (0) 5 (2.6) 0 (0) 5 (2.6)
Mutation, no./total no. (%)
FLT3 1/23 (4.3) 53/168 (31.5) 0.005 0/18 (0) 53/168 (31.5) 0.002 1/5 (20) 53/186 (28.4) 1.000
NPM1 1/23 (4.3) 51/168 (30) 0.006 0/18 (0) 51/168 (30.3) 0.004 1/5 (20) 51/186 (27.4) 1.000
DNMT3A 4/23 (17.4) 43/168 (25.6) 0.453 2/18 (11.1) 43/168 (25.6) 0.249 2/5 (40) 45/186 (24.2) 0.598
IDH1 or IDH2 1/23 (4.3) 34/168 (20.2) 0.084 0/18 (0) 34/168 (20.2) 0.048 1/5 (20) 34/186 (18.3) 1.000
NRAS or KRAS 3/23 (13) 20/168 (11.9) 0.744 3/18 (16.7) 20/168 (11.9) 0.471 0/5 (0) 23/186 (12.4) 1.000
RUNX1 2/23 (8.7) 17/168 (10.1) 1.000 0/18 (0) 17/168 (10.1) 0.380 2/5 (40) 17/186 (9.1) 0.078
TET2 1/23 (4.3) 15/168 (8.9) 0.698 1/18(5.6) 15/168 (8.9) 1.000 0/5 (0) 16/186 (8.6) 1.000
TP53 15/23 (65.2) 1/168 (0.6) <0.0001 13/18 (72.2) 1/168 (0.6) <0.0001 2/5 (40) 14/186 (7.5) 0.057
CEBPA 2/23 (8.7) 10/168 (6.0) 0.641 2/18 (11.1) 10/168 (6.0) 0.327 0/5 (0) 12/186 (6.5) 1.000
WT1 0/23 (0) 12/168 (7.1) 0.366 0/18 (0) 12/168 (7.1) 0.610 0/5 (0) 12/186 (6.5) 1.000
PTPN11 2/23 (8.7) 6/168 (3.6) 0.248 2/18 (11.1) 6/168 (3.6) 0.175 0/5 (0) 8/186 (4.3) 1.000
KIT 1/23 (4.3) 6/168 (3.6) 0.599 0/18 (20) 6/168 (3.6) 1.000 1/5 (20) 6/186 (3.2) 0.172
Significant P values are in bold
CNV copy number variation, BM bone marrow, WBC white blood cell
aExcluding samples with m6A regulatory gene mutations
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